| Catalog No. | Size | Price (USD) |
| 103780-T08-50 | 50 µL | $147.96 |
| 103780-T08-100 | 100 µL | $251.64 |
| 103780-T08-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-CLPTM1L Antibody, Rabbit Polyclonal |
| Validated applications | IHC-P (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human CLPTM1L |
| Immunogen | A synthetic peptide corresponding to the C-terminus of the Human CLPTM1L |
| Preparation | Produced in rabbits immunized with a synthetic peptide corresponding to the C-terminus of the Human CLPTM1L , and purified by antigen affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A & Antigen Affinity |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-CRR9 Antibody; Anti-FLJ14400 Antibody
Image / Experimental Information
| Image 1 Description | Immunochemical staining of human CLPTM1L in human hepatoma with rabbit polyclonal antibody (1:1000, formalin-fixed paraffin embedded sections). |
| Image 1 Alt Text | Human CLPTM1L Immunohistochemistry(IHC) 15455 |
| Image 1 URL | Source image |
| Image 2 Description | Immunochemical staining of human CLPTM1L in human hepatoma with rabbit polyclonal antibody (1:1000, formalin-fixed paraffin embedded sections). |
| Image 2 Alt Text | Human CLPTM1L Immunohistochemistry(IHC) 15456 |
| Image 2 URL | Source image |
Background Information
| Description | Cleft Lip and Palate Transmembrane 1-Like (CLPTM1L)/Cisplatin Resistance Related Protein 9 (CRR9), located on chromosome 5p15.33, affects multiple survival signaling pathways in tumor cells under oncogenic, genotoxic, and microenvironmental stress. The transmembrane protein CLPTM1L is overexpressed in non-small cell lung cancer, where it protects tumor cells from genotoxic apoptosis. RNA interference-mediated blockade of CLPTM1L inhibits K-Ras-induced lung tumorigenesis. CLPTM1L interacts with phosphoinositide 3-kinase and is essential for Ras-induced AKT phosphorylation. The anti-apoptotic protein Bcl-xL is regulated by CLPTM1L independently of AKT activation. Constitutive activation of AKT or Bcl-xL rescued the transformed phenotype in CLPTM1L-depleted cells. CLPTM1L is associated with lung cancer and it may be associated with anti-apoptotic mechanism which affects drug-resistance. CLPTM1L plays a protumorigenic role in Ras-driven lung cancers, with potential implications for therapy and chemosensitization. |
| References |
|
-HD10MA3011-1ug-hepatoma-IHC-P.png){kind=link}
-HD10MA3011-1ug-thyroid-cancer-IHC-P.png){kind=link}